
Tecentriq1200 mg/vi
Roche Bangladesh Ltd.
Established (FDA-Approved) Indications Atezolizumab is a PD-L1 immune checkpoint inhibitor approved, alone or in combination with other anticancer agents and more.
Atezolizumab is a PD-L1 immune checkpoint inhibitor approved, alone or in combination with other anticancer agents, for the treatment of several malignancies under oncology specialist supervision:
Note: Some earlier accelerated-approval indications of Atezolizumab in urothelial carcinoma have since been withdrawn in certain markets following confirmatory trial results; use in that setting should follow current local regulatory and oncology guideline status.
All uses of Atezolizumab require confirmation of diagnosis, staging, and (where specified) biomarker (PD-L1) testing, and must be initiated and monitored by a qualified oncology specialist.
| Indication | Recommended Dose | Frequency |
|---|---|---|
| NSCLC / SCLC / HCC / Melanoma (adult, most regimens) | 1200 mg IV | Every 3 weeks |
| Alternative dosing (select regimens) | 1680 mg IV | Every 4 weeks |
| Alternative dosing (select regimens) | 840 mg IV | Every 2 weeks |
The specific dose and schedule of Atezolizumab depend on the cancer type, disease stage, and the combination regimen being used, and must be individualized by the treating oncologist.
Atezolizumab must be diluted in 0.9% Sodium Chloride Injection before use and administered as an intravenous infusion only — never as an intravenous push or bolus. The first infusion is given over 60 minutes; if well tolerated, subsequent infusions may be given over 30 minutes. Atezolizumab should not be mixed with, or administered as an infusion with, other medicinal products, and should be given through a dedicated line.
Patients should be monitored during and for at least the first hour after infusion for signs of infusion-related reactions.
See Precautions and Warnings for full detail on immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, skin reactions, and others) and infusion-related reactions associated with Atezolizumab.
Atezolizumab is contraindicated in patients with a known severe hypersensitivity reaction to Atezolizumab or to any of its excipients.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.